We’re testing a new AI assistant to help patients, caregivers, and researchers find information faster. Click the FCF Assistant button in the lower right corner to try it.
Kurt Losert 
In a study funded by FCF, scientists at the Princess Máxima Center for pediatric oncology and the Hubrecht Institute in the Netherlands have revealed new insights into the features of fibrolamellar carcinoma (FLC). Their findings, published this week in Nature Communications, may help in developing new drug therapies in the future. The study, led by …
This week, approximately 70 cancer specialists from U.S. and international research institutions gathered in Greenwich, Connecticut to collaborate share research information about fibrolamellar carcinoma (FLC). For the 5th time, the Fibrolamellar Cancer Foundation sponsored an international symposium designed to bring together the community of researchers investigating FLC, foster deeper collaboration among those teams, and accelerate …
FCF is pleased to announce that Dr. Taran Gujral of the Fred Hutchinson Cancer Center in Seattle, Washington has been awarded a two-year grant. Dr. Gujral studies both tumor cells and their microenvironment. His lab has been developing new patient-derived xenograft (PDX) and cell culture models from human FLC tumors to facilitate the search for …
FCF is pleased to announce that we have awarded Dr. Julien Sage of Stanford University a one-year grant entitled “Development of pre- clinical murine models for fibrolamellar hepatocellular carcinoma”. Dr. Sage is recognized as a world leader in using genome-editing to develop and study genetically-engineered mouse models for human cancers, including lung cancer, pancreatic cancer, …
The EveryLife Foundation has announced a scholarship opportunity for rare disease patients. If you are 17 or older and a resident of the United States who has been diagnosed as having any form of rare disease, you are invited to apply for the #RAREis Scholarship Fund. Under this program, the EveryLife Foundation plans to award up to seventy …
A new study, recently published in Nature Precision Oncology, indicates that the incidence rate of fibrolamellar carcinoma (FLC) may be significantly higher than commonly cited statistics for the disease. The study, led by Dr. Travis Zack, Dr. John Gordan and Kurt Losert, combined a detailed analysis of electronic medical records (EMR) from a healthcare system …
February 28th is Rare Disease Day — a worldwide event hoping to improve the lives of the 300 million people worldwide who are living with rare diseases by raising awareness about the impact of rare diseases among policy makers, the scientific community and the general public. It was launched in 2008 by EURODIS and takes place on the …
A new study, recently published in eLife by Dr. John Gordan of UCSF, elaborates some of the downstream effects of protein kinase A (PKA) in certain cancers, including fibrolamellar. Genetic alterations that activate PKA are found in many cancer types (such as the DNAJB1-PRKACA fusion in FLC), but how that signalling leads to cancer formation …
Amara Strande, a FLC patient, and her family have joined legislators in Minnesota to advocate for changes to protect communities from toxic chemicals. “2022 is the year my cancer became unstoppable,” 20-year-old Amara Strande said in her presentation to the committee. “They can’t do surgery this time. There are no more treatments to try,” Strande …